UBS Group’s Starling Oncology Warrant STLNW Stock Holding History

UBS Group’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$702	Buy	+17,115	New	+$816	﹤0.01%	9752
2025 Q3	–	Sell	-3,670	Closed	-$187	–	10931
2025 Q2	$187	Buy	3,670 +649	+21%	+$41	﹤0.01%	9937
2025 Q1	$82	Sell	3,021 -85	-3%	-$2	﹤0.01%	9966
2024 Q4	$16	Sell	3,106 -2,977	-49%	-$46	﹤0.01%	9787
2024 Q3	$122	Sell	6,083 -2,706	-31%	-$54	﹤0.01%	9138
2024 Q2	$229	Buy	+8,789	New	+$678	﹤0.01%	9058
2023 Q4	–	Sell	-1,034	Closed	-$88	–	9891
2023 Q3	$88	Buy	+1,034	New	+$84	﹤0.01%	8916
2023 Q1	–	Sell	-610	Closed	-$67	–	10378
2022 Q4	$67	Sell	610 -4,889	-89%	-$1.59K	﹤0.01%	10448
2022 Q3	$3K	Buy	5,499 +25	+0.5%	+$17	﹤0.01%	9587
2022 Q2	$3K	Buy	5,474 +1,000	+22%	+$920	﹤0.01%	9368
2022 Q1	$5K	Buy	4,474 +102	+2%	+$93	﹤0.01%	9169
2021 Q4	$3K	Buy	+4,372	New	+$5.41K	﹤0.01%	9696

Other funds holding STLNW

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

UBS Group's STLNW Position: Q2 2026 in Review

UBS Group opened a new position in Starling Oncology Warrant (STLNW) in Q2 2026: 17,115 shares worth $702. The stake represents ﹤0.01% of the portfolio and ranks #9752 among its holdings. This is a return to the name: UBS Group previously reported a position in STLNW as recently as Q2 2025.

UBS Group first reported a position in STLNW in Q4 2021 and has held it in 12 quarters since. The position peaked at $5K in Q1 2022. 12 funds tracked by Wall St. Rank hold STLNW as of Q2 2026.

UBS Group held 17,115 shares of Starling Oncology Warrant worth $702 as of Q2 2026.
Starling Oncology Warrant was a new UBS Group position in Q2 2026.
Starling Oncology Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9752 holding.
UBS Group first reported a position in Starling Oncology Warrant in Q4 2021 and has held it in 12 quarters since.
UBS Group's Starling Oncology Warrant position peaked at $5K in Q1 2022.
12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.